Although epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors have been used to treat ESCC therapeutically, patients initially benefiting from targeted therapies inevitably develop drug resistance (4, 5); therefore, it remains a worthwhile endeavor to investigate novel effective therapeutic targets and inhibitors to overcome these challenges. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.